Press Releases

Press Releases

Samsung Biologics reveals turnaround in Q3 with KRW 184.8 billion in sales and KRW 23.6 billion in operating profit

Samsung Biologics reveals turnaround in Q3 with KRW 184.8 billion in sales and KRW 23.6 billion in operating profit

 

Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its business performance for the third-quarter in 2019, posting revenue of KRW 184.8 billion, operating profit of KRW 23.6 billion, and net profit of KRW 44.2 billion.

 

Sales increased by KRW 106.7 billion (136.6%) compared to the previous quarter as a result of the end of Slow-Down* for regular maintenance at plant 1 and plant 2, and sales recognition of products manufactured for PPQ (Process Performance Qualification) run at P3.

Operating profit increased by KRW 39 billion due to increased utilization rate at plant 1 and plant 2, and decreased SG&A.

 

Net profit increased by KRW 57.5 billion in a turnaround from the previous quarter, due to increased operating profit and equity method gain from affiliated companies.

 

Compared to the same quarter last year, sales increased by KRW 83.7 billion (82.8%), operating profit by KRW 13.1 billion (124.8%), and net profit by KRW 71.1 billion.

 


Samsung Biologics Financial Result 3Q 2019                    (Billion KRW)

 

'19. 3Q

'19. 3Q

QoQ

'18. 3Q

YoY

Sales

184.8

78.1

+106.7 (136.6%)

101.1

+83.7 (82.8%)

Operating 

Profit

23.6

-15.4

+39 (turnaround)

10.5

+13.1 (124.8%)

Net Profit

44.1

-13.4

+57.5 (turnaround)

-27

+71.1 (turnaround)

 

* Slow-Down:

 

Regular maintenance essential for biopharmaceutical manufacturing ? the plant operation rate temporarily decreases during this period.

 

Typically held every two years, activities essential to optimize productivity and efficiency of the plant and consumable parts replacements take place all at once. 

Samsung Biologics reveals turnaround in Q3 with KRW 184.8 billion in sales and KRW 23.6 billion in operating profit

 

Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its business performance for the third-quarter in 2019, posting revenue of KRW 184.8 billion, operating profit of KRW 23.6 billion, and net profit of KRW 44.2 billion.

 

Sales increased by KRW 106.7 billion (136.6%) compared to the previous quarter as a result of the end of Slow-Down* for regular maintenance at plant 1 and plant 2, and sales recognition of products manufactured for PPQ (Process Performance Qualification) run at P3.

Operating profit increased by KRW 39 billion due to increased utilization rate at plant 1 and plant 2, and decreased SG&A.

 

Net profit increased by KRW 57.5 billion in a turnaround from the previous quarter, due to increased operating profit and equity method gain from affiliated companies.

 

Compared to the same quarter last year, sales increased by KRW 83.7 billion (82.8%), operating profit by KRW 13.1 billion (124.8%), and net profit by KRW 71.1 billion.

 


 Samsung Biologics Financial Result 3Q 2019                    (Billion KRW)

 

'19. 3Q

'19. 3Q

QoQ

'18. 3Q

YoY

Sales

184.8

78.1

+106.7 (136.6%)

101.1

+83.7 (82.8%)

Operating 

Profit

23.6

-15.4

+39 (turnaround)

10.5

+13.1 (124.8%)

Net Profit

44.1

-13.4

+57.5 (turnaround)

-27

+71.1 (turnaround)

 

* Slow-Down:

 

Regular maintenance essential for biopharmaceutical manufacturing – the plant operation rate temporarily decreases during this period.

 

Typically held every two years, activities essential to optimize productivity and efficiency of the plant and consumable parts replacements take place all at once. 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION